SAB Biotherapeutics Other Current Liabilities

SAB Biotherapeutics (SABS) currently reports a other current liabilities of $5.4M as of March 2026. That compares with $6.1M in the prior-year period — down 11.1% year over year. Use the charts on this page to explore SAB Biotherapeutics's other current liabilities history and peer comparisons.

SAB Biotherapeutics's other current liabilities decreased from $6.1M to $5.4M — a 11.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SAB Biotherapeutics reported $5.4M in other current liabilities as of March 2026. That compares with $6.1M in the prior-year period — down 11.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $5.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SAB Biotherapeutics, and consider following SABS for alerts when major investors trade the stock.